Public Release:  Breast cancer prognosis associated with oncometabolite accumulation

Journal of Clinical Investigation

The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the National Cancer Institute discovered an association between the oncometabolite 2-hydroxyglutarate (2-HG) levels, DNA methylation patterns, and breast cancer prognosis. The authors identified a breast cancer subtype with high levels of 2-HG, and a district DNA methylation pattern that was associated with reduced survival. This breast cancer subtype was common in African-American breast cancer patients, who as a group have a high prevalence of aggressive breast cancers. This study indicates that evaluation of 2-HG along with DNA methylation may be a useful biomarker for breast cancer diagnosis and prognosis

###

TITLE: MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis

AUTHOR CONTACT: Stefan Ambs
National Cancer Institute, Bethesda, MD, USA
Phone: 301-496-4668; E-mail: ambss@mail.nih.gov

View this article at: http://www.jci.org/articles/view/71180?key=e428ff2ab0218ea590e1

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.